Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE)

Heart Rhythm

Volumn 10, Issue 6, 2013, Pages 838-846

  Schliamser, Jorge E ^a   Kadish, Alan H ^a,b,c   Subacius, Haris ^a   Shalaby, Alaa ^d   Schaechter, Andi ^a   Levine, Joseph ^e   Goldberger, Jeffrey J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TOURO COLLEGE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e ST FRANCIS HOSPITAL   (United States)

Author keywords

Implantable cardioverter defibrillator; Nonischemic cardiomyopathy; Sudden cardiac death

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DEFIBRILLATOR; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPENSITY SCORE; STROKE VOLUME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883245583     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2013.02.017     Document Type: Article

References (19)

1. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350: 2151-2158.
2. Epstein AE, Carlson MD, Fogoros RN, Higgins SL, Venditti FJ, Jr. Classification of death in antiarrhythmia trials. J Am Coll Cardiol 1996;27: 433-442.
3. Rashba EJ, Estes NA, Wang P, et al. Preserved heart rate variability identifies low-risk patients with nonischemic dilated cardiomyopathy: results from the DEFINITE trial. Heart Rhythm 2006;3: 281-286.
4. Flaherty JD, Rossi JS, Fonarow GC, et al. Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: findings from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2009;157: 1018-1025.
5. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158: 422-430.
6. Taylor AJ, Bindeman J, Feuerstein I, et al. Community-based provision of statin and aspirin after the detection of coronary artery calcium within a community-based screening cohort. J Am Coll Cardiol 2008;51: 1337-1341.
7. Ferrante D, Varini S, Macchia A, et al. Long-term results after a telephone intervention in chronic heart failure: DIAL (Randomized Trial of Phone Intervention in Chronic Heart Failure) follow-up. J Am Coll Cardiol 2010;56: 372-378.
8. Yancy CW, Wang TY, Ventura HO, et al. The coalition to reduce racial and ethnic disparities in cardiovascular disease outcomes (credo): why credo matters to cardiologists. J Am Coll Cardiol 2011;57: 245-252.
9. Williams DR. Socioeconomic differentials in health: a review and redirection. Soc Psychol Q 1990;53: 81-99.
10. Pappas G, Queen S, Hadden W, Fisher G. The increasing disparity in mortality between socioeconomic groups in the United States, 1960 and 1986. N Engl J Med 1993;329: 103-109.
11. Spertus JA, Jones PG, Masoudi FA, Rumsfeld JS, Krumholz HM. Factors associated with racial differences in myocardial infarction outcomes. Ann Intern Med 2009;150: 314-324.
12. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN, The V-HeFT VA Cooperative Studies Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 1993;87:VI17-VI23.
13. Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997;96: 2197-2205.
14. Saab AA. ICD patients whose ejection fraction improves above 35% with medical therapy are still at risk for appropriate shocks and therapy. Circulation 2011;124:A11435.
15. Schaer B, Theuns DA, Sticherling C, Szili-Torok T, Osswald S, Jordaens L. Effect of implantable cardioverter-defibrillator on left ventricular ejection fraction in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2010;106: 1640-1645.
16. Bogun FM, Desjardins B, Good E, et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol 2009;53: 1138-1145.
17. Goldberger JJ, Cain ME, Hohnloser SH, et al. AHA/ACC/HRS scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death. Circulation 2008;118: 1497-1518.
18. Goldenberg I, Mathew J, Moss AJ, et al. Corrected QT variability in serial electrocardiograms in long QT syndrome: the importance of the maximum corrected QT for risk stratification. J Am Coll Cardiol 2006;48: 1047-1052.
19. Ellenbogen KA, Levine JH, Berger RD, et al. Are implantable cardioverter-defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006;113: 776-782.